Open Actively Recruiting

Registry Study of Revcovi Treatment in Patients With ADA-SCID

About

Brief Summary

The objective of this study is to develop a registry of patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) treated with Revcovi™ that contains clinical and biochemical assessments for safety and dose adjustment based on adenosine deaminase (ADA) activity and erythrocyte deoxyadenosine nucleotide (dAXP) levels as well as immunologic monitoring.

Study Type
observational_patient_registry
Phase
Phase IV

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
N/A
Maximum Age
65 Years

Inclusion Criteria:

  • Patients with diagnosis of ADA-SCID who require ERT with ADA as judged by the treating physicians, based on the medical history, biochemical test or genotyping.
  • Understanding and willing to comply with the Registry recommendations via signed and dated written informed consent/assent.
  • ADA-SCID patient requiring Revcovi as an ERT.

Exclusion Criteria:

  • Any condition that, in the opinion of the Investigator, makes the patient unsuitable for the study.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
19-000797
Category
Pediatrics
Contact
Alexis Stephens
Location
  • UCLA Westwood
For Providers
NCT No.
NCT03878069
For detailed technical eligibility, visit ClinicalTrials.gov.